Helmut R. Maëcke

Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data

Michael Hofmann, Helmut R. Maëcke, A. Börner et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 541 citations

Medicine, Nuclear Medicine, Radiology +14

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Christian Waldherr, Miklos Pless, Helmut R. Maëcke et al. · PubMed · 2002 · 446 citations

Medicine, Oncology, Pharmacology +15

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study

Christian Waldherr, Misha Pless, Helmut R. Maëcke et al. · Annals of Oncology · 2001 · 394 citations

Medicine, Nuclear Medicine, Oncology +11

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

Pedro Antunes, Mihaela Ginj, Hanwen Zhang et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2007 · 392 citations · Full text

Medicine, Oncology, Radiology +13

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

Dik J. Kwekkeboom, Jan Mueller‐Brand, Giovanni Paganelli et al. · PubMed · 2005 · 375 citations · Full text

Medicine, Nuclear Medicine, Oncology +17